Peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers

Patent metadata

Field	Value
Publication number	US-10064926-B2
Application number	US-201514975952-A
Country	US
Kind code	B2
Filing date	Dec 21, 2015
Priority date	Dec 23, 2014
Publication date	Sep 4, 2018
Grant date	Sep 4, 2018

Abstract

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. In particular, the present invention relates to several novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses or as targets for the development of pharmaceutically/immunologically active compounds and cells.

First claim

The invention claimed is:

1. A peptide consisting of the amino acid sequence of SLFGQDVKAV (SEQ ID NO: 255) in the form of a pharmaceutically acceptable salt, wherein the pharmaceutically acceptable salt is a hydrochloride salt.

2. The peptide according to claim 1 , wherein said peptide has the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I or -II, and wherein said peptide, when bound to MHC, is capable of being recognized by CD4 and/or CD8 T cells.

3. A modified peptide consisting of the amino acid sequence of SLFGQDVKAV (SEQ ID NO: 255), wherein a non-peptide bond replaces a peptide bond, wherein the non-peptide bond is selected from the group consisting of reverse peptide bond (—NH—CO—), —CH 2 —NH, —CH 2 S—, —CH 2 CH 2 —, —CH═CH—, —COCH 2 —, —CH(OH)CH 2 —, and —CH 2 SO—.

4. A fusion protein comprising a peptide consisting of the amino acid sequence of SLFGQDVKAV (SEQ ID NO: 255) and N-terminal amino acids of the HLA-DR antigen-associated invariant chain (Ii).

Assignees

• Immatics Biotechnologies Gmbh

Inventors

• Weinschenk Toni
• Mahr Andrea
• Fritsche Jens
• Mueller Phillip
• Wiebe Anita
• Kutscher Sara

Classifications

• A61P37/04

  Immunostimulants · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P13/12

  of the kidneys · CPC title

• A61P1/18

  for pancreatic disorders, e.g. pancreatic enzymes · CPC title